The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties
about
Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemiaThe epigenetic landscape of acute myeloid leukemiaPrevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupChromosomal instability and cancer: a complex relationship with therapeutic potentialIdentification of AML1-ETO modulators by chemical genomicsPrognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyDNA sequencing of a cytogenetically normal acute myeloid leukaemia genomeCytogenetic features in myelodysplastic syndromesComputer aided analysis of additional chromosome aberrations in Philadelphia chromosome positive acute lymphoblastic leukaemia using a simplified computer readable cytogenetic notationCross-platform analysis of cancer microarray data improves gene expression based classification of phenotypesDetermination of caspase-3 activation fails to predict chemosensitivity in primary acute myeloid leukemia blasts.Stem Cell Modeling of Core Binding Factor Acute Myeloid LeukemiaVolasertib for AML: clinical use and patient considerationCore Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic OpportunitiesHow I treat pediatric acute myeloid leukemiaConcise review: Leukemia stem cells in personalized medicineChildhood acute myeloid leukaemiaAnimal models of leukemia: any closer to the real thing?Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyNext-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutationsGenomic Classification and Prognosis in Acute Myeloid Leukemia.Erythroleukaemia in the north of England: a population based studyAdult acute erythroleukemia: an analysis of 91 patients treated at a single institutionAcute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classificationIn vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AMLOverexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim inductionCorrelation analysis of two-dimensional gel electrophoretic protein patterns and biological variables.Establishment of a prediction model of changing trends in cardiac hypertrophy disease based on microarray data screening.Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survivalA single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialThe European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.Acute promyelocytic leukemia with the translocation t(15;17)(q22;q21) associated with t(1;2)(q42~43;q11.2~12): a case reportLeukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemiaGlobal Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia PatientsLeukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemiaFailure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia.Granulocytic sarcoma of the pancreas: a case report and review of the literatures.Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.
P2860
Q21144312-A6B68D33-EBEA-4928-AE6E-251F180B879EQ21284742-24B6691C-A3B1-4E3A-B8B3-4F8AAAFD0E73Q24602856-95528BEB-FBA2-4BD4-B6E5-ACE407033DF4Q24608609-75AC5C0F-A75B-44D5-969C-A00F31654F73Q24643359-B12C5B35-89CC-4DAB-B2C4-BA21AD3574F2Q24643738-371B8309-41BA-4384-9B16-BAA4D5A356F2Q24644436-4786A396-7CD9-4654-A890-CA32B7D2E2B3Q24644654-106CD560-C116-435B-9458-16CED9775149Q24798120-DDC74F5B-0BD3-4CDD-9F0C-04781DDF9273Q24811346-3F0236CD-349B-4A63-88EE-DEDFDEC57677Q24814114-C0E272C5-C11C-4B0F-9E36-505CBB963204Q26765858-CBEF2AE4-A4DB-4769-AE54-8CA641C2E67BQ26801131-C06E40E0-87DC-4BC3-95E9-C251CDF5F607Q26863756-34F2164D-794A-4371-A5FF-39022F40D957Q26992280-66683035-F684-4BFE-A0BF-F3F7D7520519Q26995268-20AFEF10-20F8-4F23-BA5F-295B38F509A4Q27005960-B643FF04-ADD8-4FB5-A1B4-E750D5FB014EQ27026520-EEBBED1D-DC7A-4A87-A142-743EE316A1F4Q27851436-51A32884-1F49-4698-9767-7124CDA4298CQ27853094-C595ABDA-AE86-4ADE-B625-D15CABED1F32Q27853389-64B16344-05F5-467A-BA79-62A1FD7866D0Q28209576-E65DD114-89E9-44E7-91E7-AE2071DB6164Q28258018-3B4EA521-7916-4154-9708-A949B6C6F9ECQ28269007-174110B2-0B1B-47B5-AE29-3ED293AA9C66Q28475341-E75084E5-BE59-4298-AE50-C04386A6A657Q28482247-F7D72185-9569-45D0-85D9-DE24CE262A6EQ30477879-66DE8D94-14DC-47CA-87A4-8F1D8F46CE67Q31095420-FD682096-9A4A-47B8-B4F5-4BD0E2B3394BQ33318747-A3CEB24B-80A9-467B-874F-18001F07254BQ33350688-0BEC149E-46FE-42BF-BA9D-B4AA9502FC3FQ33431584-2B6ACCFA-492F-45F6-A048-0791D7416ACFQ33434158-C13F27E2-6BFE-48A2-9A95-8EAFED83EB96Q33491557-5317531C-7D48-44CF-BF59-5F862016D653Q33555287-EEB2837F-6D9D-4129-ADE5-8F3410998F36Q33558780-2E0D5938-FCD9-4464-BB62-5F070B15D58BQ33598706-52F0369E-0F4C-488A-962D-D1B89576C50CQ33601710-CD3774B1-5741-4323-A977-8BB1FA0F80CBQ33611146-5FBBD3EC-DCF3-406A-BF9C-2E8E76290721Q33630796-B534EBB4-A57F-4872-981E-82624EC4D824Q33636086-99380C00-B583-40E5-ABCD-AB4F8DD66084
P2860
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
The importance of diagnostic c ...... en's Leukaemia Working Parties
@ast
The importance of diagnostic c ...... en's Leukaemia Working Parties
@en
The importance of diagnostic c ...... en's Leukaemia Working Parties
@nl
type
label
The importance of diagnostic c ...... en's Leukaemia Working Parties
@ast
The importance of diagnostic c ...... en's Leukaemia Working Parties
@en
The importance of diagnostic c ...... en's Leukaemia Working Parties
@nl
prefLabel
The importance of diagnostic c ...... en's Leukaemia Working Parties
@ast
The importance of diagnostic c ...... en's Leukaemia Working Parties
@en
The importance of diagnostic c ...... en's Leukaemia Working Parties
@nl
P2093
P921
P3181
P1433
P1476
The importance of diagnostic c ...... en's Leukaemia Working Parties
@en
P2093
A Goldstone
C Harrison
D Grimwade
G Harrison
K Wheatley
P304
P3181
P407
P577
1998-10-01T00:00:00Z